COYA

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.

Wall Street analysts forecast COYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COYA is 17.50 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Coya Therapeutics Inc revenue for the last quarter amounts to 3.56M USD, decreased % YoY.

Coya Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -50.00 % YoY.

Coya Therapeutics Inc (COYA) has 8 emplpoyees as of January 09 2026.

Today COYA has the market capitalization of 107.13M USD.